The week in pharma: action, reaction and insight – week to March 1, 2024
By Barbra Obstoj-Cardwell. Editor
Research news last week included US biotech Amgen holding an R&D conference call outlining its ambitions and achievements in the area of rare diseases, including Tepezza and Krystexxa. Also, USA-based Viking Therapeutics released new Phase II data for its obesity hopeful VK2735. Regulatory news saw the US Food and Drug Administration (FDA) reject approval of Minerva Neurosciences’ roluperidone, issuing a complete response letter (CRL) noting a lack of efficacy evidence. Also, Franco-American firm Allecra Therapeutics received authorization from the FDA for its Exblifep for the treatment of complicated urinary tract infections (cUTIs). US pharma giant Pfizer last Thursday held an investor meeting to outline plans for its oncology business following the $43 billion acquisition of Seagen.
Amgen rare disease investor call takeaways
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze